[Federal Register Volume 87, Number 42 (Thursday, March 3, 2022)]
[Notices]
[Pages 12207-12208]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04463]
=======================================================================
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Advisory Committee on the Medical Uses of Isotopes: Charter
Renewal
AGENCY: U.S. Nuclear Regulatory Commission.
ACTION: Notice of charter renewal.
-----------------------------------------------------------------------
SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) has determined
that renewal of the charter for the Advisory Committee of the Medical
Uses of Isotopes (ACMUI) until February 28, 2024, is in the public
interest in connection with duties imposed on the Commission by law.
This action is being taken in accordance with the Federal Advisory
Committee Act, after consultation with the Committee Management
Secretariat, General Services Administration.
FOR FURTHER INFORMATION CONTACT: Donald Lowman, Office of Nuclear
Material Safety and Safeguards, U.S. Nuclear Regulatory Commission,
Washington, DC 20555; Telephone: (301) 415-5452 or at
[email protected].
SUPPLEMENTARY INFORMATION: The purpose of the ACMUI is to provide
advice to the NRC on policy and technical issues that arise in
regulating
[[Page 12208]]
the medical use of byproduct material for diagnosis and therapy.
Responsibilities include providing guidance and comments on current and
proposed NRC regulations and regulatory guidance concerning medical
use; evaluating certain non-routine uses of byproduct material for
medical use; and evaluating training and experience of proposed
authorized users. The members are involved in preliminary discussions
of major issues in determining the need for changes in NRC policy and
regulation to ensure the continued safe use of byproduct material. Each
member provides technical assistance in his/her specific area(s) of
expertise, particularly with respect to emerging technologies. Members
also provide guidance as to NRC's role in relation to the
responsibilities of other Federal agencies as well as of various
professional organizations and boards.
Members of this Committee have demonstrated professional
qualifications and expertise in both scientific and non-scientific
disciplines including nuclear medicine; nuclear cardiology; radiation
therapy; medical physics; nuclear pharmacy; State medical regulation;
patient's rights and care; health care administration; and Food and
Drug Administration regulation.
Dated at Rockville, Maryland, this 28th day of February, 2022.
For the U.S. Nuclear Regulatory Commission.
Russell E. Chazell,
Federal Advisory Committee Management Officer.
[FR Doc. 2022-04463 Filed 3-2-22; 8:45 am]
BILLING CODE 7590-01-P